Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Paclitaxel-induced Neuropathic Pain by Telmisartan in Patients With Planned Paclitaxel Chemotherapy Due to Ovarian or Breast Cancer (PrevTel)

NCT05322889 is registered in ClinicalTrials.gov with Dr. Frank Behrens as lead sponsor.

NCT NCT05322889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05322889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Paclitaxel-induced Neuropathic Pain by Telmisartan in Patients With Planned Paclitaxel Chemotherapy Due to Ovarian or Breast Cancer (PrevTel)
Lead sponsor
Dr. Frank Behrens
Phase
Phase 2
Overall status
Completed
Start date
April 9, 2020
Completion date
June 30, 2023
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, neuropathic pain